17-ジメチルアミノエチルアミノ-17-デメトキシゲルダナマイシン

17-ジメチルアミノエチルアミノ-17-デメトキシゲルダナマイシン
	IUPAC名 [(3R,5S,6R,7S,8E,10S,11S,12Z,14E)-21-(2-dimethylaminoethylamino)-6-hydroxy-5,11-dimethoxy-3,7,9,15-tetramethyl-16,20,22-trioxo-17-azabicyclo[16.3.1]docosa-1(21),8,12,14,18-pentaen-10-yl] carbamate
	別称 17-DMAG; Alvespimycin
識別情報
CAS登録番号	467214-20-6
PubChem	5288674
ChemSpider	16744073
	SMILES C[C@H]1C[C@@H]([C@@H]([C@H](/C=C(/[C@@H]([C@H](/C=C\C=C(\C(=O)NC2=CC(=O)C(=C(C1)C2=O)NCCN(C)C)/C)OC)OC(=O)N)\C)C)O)OC; C[C@H]1C[C@@H]([C@@H]([C@H](/C=C(/[C@@H]([C@H](/C=C\C=C(\C(=O)NC2=CC(=O)C(=C(C1)C2=O)NCCN(C)C)/C)OC)OC(=O)N)\C)C)O)OC;
	InChI InChI=1S/C32H48N4O8/c1-18-14-22-27(34-12-13-36(5)6)24(37)17-23(29(22)39)35-31(40)19(2)10-9-11-25(42-7)30(44-32(33)41)21(4)16-20(3)28(38)26(15-18)43-8/h9-11,16-18,20,25-26,28,30,34,38H,12-15H2,1-8H3,(H2,33,41)(H,35,40)/b11-9-,19-10+,21-16+/t18-,20+,25+,26+,28-,30+/m1/s1 Key: KUFRQPKVAWMTJO-LMZWQJSESA-N; InChI=1/C32H48N4O8/c1-18-14-22-27(34-12-13-36(5)6)24(37)17-23(29(22)39)35-31(40)19(2)10-9-11-25(42-7)30(44-32(33)41)21(4)16-20(3)28(38)26(15-18)43-8/h9-11,16-18,20,25-26,28,30,34,38H,12-15H2,1-8H3,(H2,33,41)(H,35,40)/b11-9-,19-10+,21-16+/t18-,20+,25+,26+,28-,30+/m1/s1 Key: KUFRQPKVAWMTJO-LMZWQJSEBL;
特性
化学式	C32H48N4O8
モル質量	616.75 g mol−1
	特記なき場合、データは常温 (25 °C)・常圧 (100 kPa) におけるものである。

17-ジメチルアミノエチルアミノ-17-デメトキシゲルダナマイシン(17-dimethylaminoethylamino-17-demethoxygeldanamycin, 17-DMAG)は、抗生物質のゲルダナマイシンの半合成誘導体である^[1]^[2]。癌治療への発展性が研究されている^[3]。

出典

^ WO application 2002079167, Snader, Kenneth M.; Vishnuvajjala, B. Rao; Hollingshead, Melinda G.; Sausville, Edward A., "Preparation of geldanamycin derivatives for the treatment of cancer", published 2002
^ Rastelli, Giulio; Tian, Zong-Qiang; Wang, Zhan; Myles, David; Liu, Yaoquan (2005). “Structure-based design of 7-carbamate analogs of geldanamycin”. Bioorganic & Medicinal Chemistry Letters 15 (22): 5016–5021. doi:10.1016/j.bmcl.2005.08.013.
^ Sausville, E. A.; Tomaszewski, J. E.; Ivy, P. (2003). “Clinical development of 17-allylamino, 17-demethoxygeldanamycin.”. Curr. Cancer Drug Targets 3 (5): 377. doi:10.2174/1568009033481831. PMID 14529389.

[1] WO application 2002079167, Snader, Kenneth M.; Vishnuvajjala, B. Rao; Hollingshead, Melinda G.; Sausville, Edward A., "Preparation of geldanamycin derivatives for the treatment of cancer", published 2002

[2] Rastelli, Giulio; Tian, Zong-Qiang; Wang, Zhan; Myles, David; Liu, Yaoquan (2005). “Structure-based design of 7-carbamate analogs of geldanamycin”. Bioorganic & Medicinal Chemistry Letters 15 (22): 5016–5021. doi:10.1016/j.bmcl.2005.08.013.

[3] Sausville, E. A.; Tomaszewski, J. E.; Ivy, P. (2003). “Clinical development of 17-allylamino, 17-demethoxygeldanamycin.”. Curr. Cancer Drug Targets 3 (5): 377. doi:10.2174/1568009033481831. PMID 14529389.

[1]

[2]

[3]